Leerink Partnrs Issues Negative Estimate for Pfizer Earnings

Key Points

• Leerink Partners has lowered its Q3 2025 earnings per share estimate for Pfizer from $0.98 to $0.80, indicating a more pessimistic outlook for the biopharmaceutical company's earnings.
• Despite the negative forecast, Pfizer recently reported strong quarterly earnings of $0.78 per share, exceeding analysts’ expectations and showing a revenue increase of 10.3% year-over-year.
• Analyst ratings for Pfizer are mixed, with a consensus rating of "Moderate Buy", reflecting a range of opinions among market analysts regarding the future performance of the stock.

Pfizer Inc. (NYSE:PFE - Free Report) - Equities researchers at Leerink Partnrs reduced their Q3 2025 EPS estimates for shares of Pfizer in a research report issued on Tuesday, August 5th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings per share of $0.80 for the quarter, down from their prior forecast of $0.98. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share. Leerink Partnrs also issued estimates for Pfizer's Q4 2025 earnings at $0.64 EPS, FY2026 earnings at $3.27 EPS and FY2028 earnings at $2.59 EPS.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.33%. The firm had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same period in the previous year, the company earned $0.60 EPS. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year.

A number of other equities research analysts have also weighed in on the stock. HSBC decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. TD Cowen reduced their price target on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a report on Tuesday, April 22nd. Bank of America boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday. Morgan Stanley boosted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday. Finally, BMO Capital Markets reduced their price objective on shares of Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and a consensus price target of $28.44.

Pfizer Price Performance

PFE stock opened at $23.95 on Thursday. Pfizer has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The company has a 50-day moving average price of $24.40 and a 200 day moving average price of $24.53. The stock has a market cap of $136.15 billion, a PE ratio of 12.74, a P/E/G ratio of 0.90 and a beta of 0.52.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is 124.64%.

Institutional Trading of Pfizer

Several large investors have recently made changes to their positions in the business. Bessemer Group Inc. boosted its holdings in Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after buying an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK boosted its holdings in Pfizer by 1.2% during the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock worth $35,817,000 after buying an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp purchased a new stake in Pfizer during the first quarter worth $8,283,000. Alta Advisers Ltd boosted its holdings in Pfizer by 69.6% during the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock worth $809,000 after buying an additional 13,100 shares in the last quarter. Finally, WCM Investment Management LLC boosted its holdings in Pfizer by 8.7% during the first quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock worth $3,176,000 after buying an additional 10,051 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.